Immune Biomarkers on Tissue Microarray Cores Support the Presence of Adjacent Tertiary Lymphoid Structures in Soft Tissue Sarcoma.

IF 5.1 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Laboratory Investigation Pub Date : 2025-01-10 DOI:10.1016/j.labinv.2025.104091
Elahe Shenasa, Shelby Thornton, Dongxia Gao, Felix Kommoss, Torsten O Nielsen
{"title":"Immune Biomarkers on Tissue Microarray Cores Support the Presence of Adjacent Tertiary Lymphoid Structures in Soft Tissue Sarcoma.","authors":"Elahe Shenasa, Shelby Thornton, Dongxia Gao, Felix Kommoss, Torsten O Nielsen","doi":"10.1016/j.labinv.2025.104091","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy has emerged as a new treatment modality in some soft tissue sarcomas, particularly for tumors associated with tertiary lymphoid structures (TLS). These structures are functional lymphoid aggregates, and their presence is indicative of an active anticancer immune response in the tumor microenvironment. The assessment of TLS as a predictive biomarker at scale on patient specimens remains challenging. While tissue microarrays could facilitate this assessment, it is unclear whether small microarray cores can represent and identify associated TLS responses. We sought to use multiplex immunohistochemistry to identify key components of TLS: T cells, B cells, and dendritic cells. The multiplex panels (CD3, CD20, CD208 and PNAd) were applied onto 80 cases both on tissue microarrays and on their cognate available full-faced sections from epithelioid sarcoma and dedifferentiated/well-differentiated liposarcoma case series. Tissue microarrays were digitally scored for the number of immune cells using the HALO image analysis platform, and cognate full-faced sections were visually evaluated for the presence of TLS. An independent validation set of soft tissue sarcomas (N=49) was stained with the CD3, CD20, and CD208, and scored by QuPath. A Combined Immune Marker (defined as the presence of more than more than 24% CD3+T cell, or 0.51% CD20+B cell, or more than 0.14% CD208+mature dendritic cell on tissue microarray core) is highly specific (100%) and moderately sensitive (61%) to predict the existence of TLS on full-faced sections. The Combined Immune Marker showed a sensitivity of 25% and specificity of 91% on the validation set. The Combined Immune Marker assessed on tissue microarrays is highly specific to infer the presence of TLS present on cognate full-faced sections. Therefore, despite the small area sampled, tissue microarrays may be utilized to assess the clinical value of TLS on datasets where specificity is critical and large sample size can mitigate low to moderate sensitivity.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104091"},"PeriodicalIF":5.1000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.labinv.2025.104091","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Immunotherapy has emerged as a new treatment modality in some soft tissue sarcomas, particularly for tumors associated with tertiary lymphoid structures (TLS). These structures are functional lymphoid aggregates, and their presence is indicative of an active anticancer immune response in the tumor microenvironment. The assessment of TLS as a predictive biomarker at scale on patient specimens remains challenging. While tissue microarrays could facilitate this assessment, it is unclear whether small microarray cores can represent and identify associated TLS responses. We sought to use multiplex immunohistochemistry to identify key components of TLS: T cells, B cells, and dendritic cells. The multiplex panels (CD3, CD20, CD208 and PNAd) were applied onto 80 cases both on tissue microarrays and on their cognate available full-faced sections from epithelioid sarcoma and dedifferentiated/well-differentiated liposarcoma case series. Tissue microarrays were digitally scored for the number of immune cells using the HALO image analysis platform, and cognate full-faced sections were visually evaluated for the presence of TLS. An independent validation set of soft tissue sarcomas (N=49) was stained with the CD3, CD20, and CD208, and scored by QuPath. A Combined Immune Marker (defined as the presence of more than more than 24% CD3+T cell, or 0.51% CD20+B cell, or more than 0.14% CD208+mature dendritic cell on tissue microarray core) is highly specific (100%) and moderately sensitive (61%) to predict the existence of TLS on full-faced sections. The Combined Immune Marker showed a sensitivity of 25% and specificity of 91% on the validation set. The Combined Immune Marker assessed on tissue microarrays is highly specific to infer the presence of TLS present on cognate full-faced sections. Therefore, despite the small area sampled, tissue microarrays may be utilized to assess the clinical value of TLS on datasets where specificity is critical and large sample size can mitigate low to moderate sensitivity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
组织微阵列核心上的免疫生物标志物支持软组织肉瘤中邻近三级淋巴结构的存在。
免疫治疗已成为一些软组织肉瘤的一种新的治疗方式,特别是与三级淋巴结构(TLS)相关的肿瘤。这些结构是功能性淋巴细胞聚集体,它们的存在表明肿瘤微环境中存在活跃的抗癌免疫反应。在患者标本上大规模评估TLS作为预测性生物标志物仍然具有挑战性。虽然组织微阵列可以促进这种评估,但尚不清楚小型微阵列核心是否可以代表和识别相关的TLS响应。我们试图使用多重免疫组织化学鉴定TLS的关键成分:T细胞、B细胞和树突状细胞。多重面板(CD3、CD20、CD208和PNAd)应用于80例上皮样肉瘤和去分化/高分化脂肪肉瘤病例系列的组织微阵列和同源全面切片。使用HALO图像分析平台对组织微阵列的免疫细胞数量进行数字评分,并对同源全面切片进行视觉评估,以确定是否存在TLS。对49例软组织肉瘤(N=49)进行CD3、CD20和CD208染色,并通过QuPath评分。联合免疫标记(定义为在组织微阵列核心上存在超过24%的CD3+T细胞,或0.51%的CD20+B细胞,或超过0.14%的CD208+成熟树突状细胞)对预测全面切片上TLS的存在具有高度特异性(100%)和中等敏感性(61%)。联合免疫标记在验证集上的敏感性为25%,特异性为91%。在组织微阵列上评估的联合免疫标记具有高度特异性,可以推断同源全面切片上存在TLS。因此,尽管取样面积小,但组织微阵列可用于评估TLS在数据集上的临床价值,其中特异性至关重要,大样本量可以减轻低至中等灵敏度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Laboratory Investigation
Laboratory Investigation 医学-病理学
CiteScore
8.30
自引率
0.00%
发文量
125
审稿时长
2 months
期刊介绍: Laboratory Investigation is an international journal owned by the United States and Canadian Academy of Pathology. Laboratory Investigation offers prompt publication of high-quality original research in all biomedical disciplines relating to the understanding of human disease and the application of new methods to the diagnosis of disease. Both human and experimental studies are welcome.
期刊最新文献
HMGB1 encapsulated in podocyte-derived exosomes plays a central role in glomerular endothelial cell injury in lupus nephritis by regulating TRIM27 expression. Leveraging Deep Learning for Immune Cell Quantification and Prognostic Evaluation in Radiotherapy-Treated Oropharyngeal Squamous Cell Carcinomas. Molecular and Immunohistochemical Classification of Extrapulmonary Small Cell Neuroendocrine Carcinomas: A Study of 181 Cases. Mono-species bacteria-induced chronic apical periodontitis triggers the aortic inflammatory response via modulation of systemic inflammation and lipid metabolism. Immune Biomarkers on Tissue Microarray Cores Support the Presence of Adjacent Tertiary Lymphoid Structures in Soft Tissue Sarcoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1